Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
09 November 2017Website:
http://www.apellis.comNext earnings report:
31 July 2024Last dividends:
N/ANext dividends:
N/APrice
regular market | 8 min agoDividend
Analysts recommendations
Institutional Ownership
APLS Latest News
Apellis (APLS) declines as CHMP issues a second negative opinion for the approval of intravitreal pegcetacoplan to treat GA in the EU. The company plans to seek re-examination of the same.
WALTHAM, Mass., June 28, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a negative opinion on the marketing authorization application (MAA) of intravitreal pegcetacoplan for the treatment of geographic atrophy (GA).
Apellis (APLS) rises 3.3% as the treatment of GA patients with Syfovre demonstrates a visual function benefit in a prespecified endpoint at month 36 in a late-stage, long-term extension study.
Apellis Pharmaceuticals (APLS) reported earnings 30 days ago. What's next for the stock?
Apellis (APLS) reports positive one-year data from the mid-stage study evaluating systemic pegcetacoplan to treat two rare and debilitating kidney diseases.
WALTHAM, Mass. and STOCKHOLM, Sweden, May 24, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) and Sobi® (STO:SOBI) today announced positive one-year results from the Phase 2 NOBLE study investigating systemic pegcetacoplan, a targeted C3 therapy, for the treatment of post-transplant recurrence of C3 glomerulopathy (C3G) and primary immune complex membranoproliferative glomerulonephritis (IC-MPGN). These data were presented during a late-breaking oral presentation at the European Renal Association (ERA) Congress taking place May 23-26 in Stockholm, Sweden.
Apellis Pharmaceuticals (APLS) lacks the necessary elements for a potential earnings surprise in its upcoming report. Be ready for the key projections.
Apellis Pharmaceuticals Inc (NASDAQ: APLS) has decreased by almost 40% from its highest point of the year, but a Mizuho analyst does not view this as a clear buying opportunity. Mizuho continues to have a "neutral" rating on Apellis Pharmaceuticals stock, as stated by analyst Graig Suvannavejh in a recent research report.
Apellis' (APLS) fourth-quarter 2023 bottom line misses estimates, while the top line meets the same. The newly approved product, Syfovre, drives year-over-year sales.
While the top- and bottom-line numbers for Apellis Pharmaceuticals, Inc. (APLS) give a sense of how the business performed in the quarter ended December 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
What type of business is Apellis Pharmaceuticals?
Reata Pharmaceuticals, Inc. is an American biopharmaceutical company founded in 2002. Based in the city of Plano, Texas, the company is involved in the development of new treatment methods based on the use of low molecular weight therapeutic agents with new mechanisms of action for the treatment of severe, life-threatening diseases. The main products of the company are bardoxolone methyl (a drug for the treatment of rare forms of chronic kidney disease (CKD)) and omaveloxolone (a drug for the treatment of rare neurological diseases). Both bardoxolone and omaveloxolone normalize mitochondrial function, restore redox balance, and eliminate inflammation. Since mitochondrial dysfunction, oxidative stress, and inflammation are features of many diseases, bardoxolone and omaveloxolone have a variety of potential clinical applications.
What sector is Apellis Pharmaceuticals in?
Apellis Pharmaceuticals is in the Healthcare sector
What industry is Apellis Pharmaceuticals in?
Apellis Pharmaceuticals is in the Biotechnology industry
What country is Apellis Pharmaceuticals from?
Apellis Pharmaceuticals is headquartered in United States
When did Apellis Pharmaceuticals go public?
Apellis Pharmaceuticals initial public offering (IPO) was on 09 November 2017
What is Apellis Pharmaceuticals website?
https://www.apellis.com
Is Apellis Pharmaceuticals in the S&P 500?
No, Apellis Pharmaceuticals is not included in the S&P 500 index
Is Apellis Pharmaceuticals in the NASDAQ 100?
No, Apellis Pharmaceuticals is not included in the NASDAQ 100 index
Is Apellis Pharmaceuticals in the Dow Jones?
No, Apellis Pharmaceuticals is not included in the Dow Jones index
When does Apellis Pharmaceuticals report earnings?
The next expected earnings date for Apellis Pharmaceuticals is 31 July 2024